Table 1.
Antiretroviral drug resistance at virological failure of TDF-containing 1st-line ART by Sanger and ultrasensitive HIV genotyping
| Subject ID | IAS-2013 mutations detected by Sanger sequencing | Additional Mutations by Illumina (Frequency in the virus population, %) | Changes in Drug Susceptibility with MiSeq™ compared to Sanger |
|---|---|---|---|
| 1 | D67N; M184I; V90I; V179E; Y181C; H221Y | G190A (4.74); K70E (4.5); P225H (8); V106I (9.4) | TDF (S→I); ETR (I→R); RPV (I→R) |
| 2 | D67N; K70E; M184V; A98G; K103N; V106M | K65R (20.3); L100I (2.1); Y181C (16,1) | TDF (I→R); ETR (I→R); RPV (I→R) |
| 3 | M184V; V106M; G190A | D67N (1.3); K103N (16,7); K65R (27.8); M184I (29.4); M230L (28.1) | TDF (S→R); RPV (I→R) |
| 4 | M184V; T215Y; V106M; Y188L | D67N (1.9); G190A (13.6); K101E (12.5) | TDF (S→I); ETR (S→I) |
| 5 | M184V; K103N; V108I | A62V (2.8); D67N (4.2); P225H (2.4) | AZT (S→I) |
| 6 | M184V; K103N; V106M | D67N (1.3); M230L (31.8) | ETR (S→I); RPV (S→I) |
| 7 | M184I; V90I; Y181C; H221Y | A98G (3.2); G190A (9.5); M184I (14.6); V179D (11.6) | ETR (I→R); RPV (I→R) |
| 8 | K70E; M184V; V90I; K103N; E138G | K65R (1.3) | TDF (I→R) |
| 9 | M184V; V106M; V108I; E138A; G190A | H221Y (1.6); K219E (2.7); K70E (8.6); L74V (3.2); V90I (8.8); Y115F (35.7) | TDF (S→I) |
| 10 | M184V; K103N; V106M | K103S (2.4) | |
| 11 | M184I; V90I; Y181C; K101E | M184V (9.9) | |
| 12 | V106M | No additional mutations found | |
| 13 | M184V; V106M; V179D | No additional mutations found | |
| 14 | K103N; P225H | V90I (1.2) | |
| 15 | No mutations found | Y188C (27.7) | |
| 16 | No mutations found | No additional mutations found | |
| 17 | Y115F; V106M; Y188C | A62V (2.4) | |
| 18 | D67G; T69N; K101E; V106M; H221Y | K65R (4.9) | TDF (S→R); AZT (S→I); 3TC (S→I); FTC (S→I) |
| 19 | M184V; A98AG; K103RST; G190A | K65R (32.5); V108I (9.8); Y181C (12.5) | TDF (S→R); ETR (S→R); RPV (I→R); |
| 20 | M184I | No additional mutations found | |
| 21 | K103N; M184V; P225H | K65R (30.5); K70E (16.4); A98G (5.8); L100I (10.8); V108I (1.5); K219Q (5.1) | TDF (S→R); ETR (S→I); RPV (I→R) |
| 22 | M184I; V106M; V179D; M230L | K65R (17.5); K70E (16.7); L74V (15.9); H221Y (4.1); F227C (29.4) | |
| 23 | M184V; V106M; G190A; F227L | Y115F (1.4) | |
| 24 | M184V; K103N; V108IV; P225HP | No additional mutations found | |
| 25 | M184V; K103N; G190A | D67N (4.6); K103S (33.1); E138G (1.2) | |
| 26 | D67N; K70E; M184V; V90IV; K101E; V106M; G190A; F227L | K103N (3.8); V179D (9.2); H221Y (1.4) | RPV (I→R) |
| 27 | M184V; V106M; V179D | A62V (12.1); K65R (11.8) | TDF (S→R) |
*
TDF: Tenofovir Disoproxyl Fumarate; ETR: Etravirine; RPV: rilpivirine; AZT: zidovudine; 3TC: lamivudine; FTC: emtricitabine.